Skip to main content
Caplight Logo









GLX Analytix

GLX Analytix

Private
CopenhagenHealthcare & Life Scienceshttps://glxanalytix.com/

Last Round

VC Round

Oct 29, 2024

Total Funding Raised

$678,253

Company Overview

GLX Analytix is a biotechnology company that operates a personalized medicine platform utilizing vascular biology and artificial intelligence to advance diagnostics and monitoring for chronic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

biomarker platformdiagnostic biomarkerprecision medicineblood-based diagnosticsliquid biopsyglycocalyx analysisearly disease detectiontreatment monitoringimmunoassaysAI diagnosticsclinical diagnosticsbiotech researchcompanion diagnosticsdigital biomarkersCDx

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GLX Analytix Comparables

Compare GLX Analytix with similar companies based on industry and business-model similarity.

GLX Analytix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Progentec Diagnostics
78%
Moleculera Biosciences
76%
Octave Bioscience
72%

GLX Analytix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundOct 29, 2024
GrantJul 5, 2024
SeedJun 14, 2022
GrantFeb 1, 2020

Key People

Founding team and executive leadership

Brian DellaValle

Chief Executive Officer Founder

Founding Team

Maital Rasmussen

Fractional Chief Commercial Officer (CCO) Advisory Board

Executive Team

GLX Analytix Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 5, 2024

    $598K grant received from Alzheimer's Drug Discovery Foundation.

  • Jun 14, 2022

    Led by DigitalDx Ventures with participation from Labcorp.

GLX Analytix Filings

Explore SEC and related filing metadata, where available.

GLX Analytix filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about GLX Analytix's valuation, stock price, and market status.

Is GLX Analytix a public or private company?

GLX Analytix is a private company.

What is the current stock price of GLX Analytix?

GLX Analytix is a private company with no public stock price. No recent secondary market data is available.

How much is GLX Analytix worth (valuation)?

Valuation information for GLX Analytix is not publicly available.

Can I buy GLX Analytix stock?

GLX Analytix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was GLX Analytix's last funding round?

GLX Analytix's most recent funding round was VC Round on October 29, 2024.

Who are the main investors in GLX Analytix?

Key investors in GLX Analytix include DigitalDx Ventures.

Will GLX Analytix IPO soon?

No public IPO plans have been announced for GLX Analytix.

How can I track GLX Analytix secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GLX Analytix's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCopenhagen
Employee Range7
Year Founded2019
Last FundingOct 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?